Issues
-
Cover Image
Cover Image
Immune checkpoint inhibitors (ICIs) have shown effectiveness in the treatment of patients with esophageal squamous carcinoma (ESCC), primarily in perioperative settings and for patients with advanced disease. In the study starting on page 669, Xiao and colleagues found that the use of ICIs in the early stage of ESCC could slow down tumor progression. In a mouse model of ESCC, preventive treatment with the PD-1 antibody at the high-grade intraepithelial neoplasia stage increased the infiltration of CD8+ tissue-resident memory T (TRM) cells, which colonized in the tumor microenvironment and continued to exert antitumor effects when the mice were re-exposed to the carcinogen 4-NQO. This study suggests that the preventive use of ICIs in ESCC may provide long-term benefits to patients. The cover image depicts infiltration of CD103+ (red) CD8+ (green) TRM cells after PD-1 antibody treatment. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Highlights from the Literature
Perspective
Spotlight
Research Briefs
A Novel Saliva and Serum miRNA Panel as a Potential Useful Index for Oral Cancer and the Association of miR-21 with Smoking History: a Pilot Study
Saliva and serum miR-21, miR-136, miR-3928, and miR-29B, are potentially associated with oral cancer even at an early stage, especially miR-21 in individuals with a smoking history, a further validation in a larger cohort of subjects with premalignant and early malignant lesions need to confirm.
Comparing Breast Cancer and Cardiovascular Disease Risk and Use of Chemoprevention and Statins among Women with High-risk Breast Lesions
Among women with high-risk breast lesions, mean absolute risk of breast cancer was higher compared with cardiovascular disease; however, statin use was significantly higher than chemoprevention. To address underutilization of breast cancer chemoprevention, these drugs should be placed in the context of medications used to prevent other chronic diseases.
Research Articles
Preventive Treatment with PD-1 Antibody Increases Tissue-resident Memory T Cells Infiltration and Delays Esophageal Carcinogenesis
Immune checkpoint inhibitors have shown promising results in multiple tumor species. However, there is currently no clinical application to evaluate their therapeutic value in cancer preventive treatment. Prophylactic use of immune checkpoint inhibitors in the early stages of ESCC may provide long-term benefits to patients.
Clinical Performance of hrHPV Primary Screening Using Vaginal versus Cervical Samples to Detect High-grade Intraepithelial Lesions
We found that hrHPV vaginal self-sampling is comparable with hrHPV clinician cervical sampling when using any triage strategy to refer women to colposcopy, so self-sampling is a viable cervical screening method. Therefore, policymakers should consider incorporating self-sampling into cervical screening programs to increase screening coverage and reduce cervical cancer burden.
Knowledge Mediates the Effects of Game Changers for Cervical Cancer Prevention (GC-CCP) Intervention on Increased VIA Screening Advocacy in Uganda
Enhancing cervical cancer knowledge among women who have screened for cervical cancer is key to empowering these women to engage in cervical cancer prevention advocacy and acting as change agents for encouraging other women to screen.
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds